Pioneering synthetic biology to engineer custom microbes for health, agriculture, and industrial applications.
Ginkgo Bioworks designs custom organisms using biotechnology and automation, enabling partners to leverage biology for production across industries such as pharmaceuticals, food, agriculture, and chemicals. By harnessing synthetic biology's potential, the company empowers innovation in therapeutics, sustainable materials, and supply chain resilience.
competitors.competitorDetail.metrics.missionStatement
To make biology easier to engineer so that we can solve the world's greatest challenges.
competitors.competitorDetail.metrics.visionStatement
To enable the bioeconomy by providing a platform where anyone can program cells as easily as computers.
competitors.competitorDetail.metrics.foundedYear
2008
competitors.competitorDetail.metrics.ceo
Jason Kelly
competitors.competitorDetail.metrics.employees
1100+
competitors.competitorDetail.metrics.revenue
$478M (2023)
competitors.competitorDetail.metrics.headquarters
27 Drydock Avenue, Boston, MA 02210, USA
competitors.competitorDetail.metrics.marketShare
Leader in U.S. synthetic biology foundry market (~40%)
competitors.competitorDetail.metrics.usp
The most advanced synthetic biology foundry for scalable, partnership-driven bioengineering.
competitors.competitorDetail.metrics.pricingModel
Partnership-based; service fees plus downstream royalties and milestone payments.
- Foundry Services
- Codebase Library
- AgriTech Solutions
- Therapeutics R&D
- Custom robotics
- Lab automation
- Proprietary bioinformatics pipelines
- Machine learning (for protein optimization)
- High-throughput genome editing
competitors.competitorDetail.metrics.marketPositioning
Innovator and platform leader in industrial-scale synthetic biology.
- Large pharmaceutical companies
- Agri-business firms
- Industrial chemical manufacturers
- Fermentation-based food producers
- Strategic partnerships
- R&D collaboration agreements
- Direct business development with enterprise clients
- Industry conference speaking
- Thought leadership content
- Collaborative PR with partners
- White papers on bioengineering breakthroughs
- Bayer (Agri-tech R&D)
- Boehringer Ingelheim (Biopharma R&D)
- Viking Global Investors (Strategic Investment)
- Full-stack organism engineering
- Bioinformatics and high throughput genome sequencing
- Strain optimization and pilot scaling
- Automated foundry for rapid prototyping
- Partnership-driven R&D
- Highly scalable automated foundry platform
- Diverse applications across several high-growth sectors
- Strong partnerships with global industry leaders
- Rapidly expanding bio data capabilities
- High R&D costs
- Complex sales cycle for partner integrations
- Reliance on continued biotech funding environment
- Growth in synbio-driven pharmaceuticals and vaccines
- Expansion into agri-tech and alternative protein markets
- Increasing demand for sustainable and bio-based manufacturing
- Regulatory changes in GMO and bioengineering sectors
- Competition from emerging synthetic biology start-ups
- Potential for technological disruption from adjacent fields
competitors.competitorDetail.metrics.growthRateYOY
68% (2022-2023)
competitors.competitorDetail.metrics.profitMargin
-130% (2023, reflecting growth investments)
competitors.competitorDetail.metrics.customerAcquisitionCost
High (custom projects with long sales cycle)
competitors.competitorDetail.metrics.customerLifetimeValue
Extensive, due to multi-year R&D partnerships and revenue sharing
competitors.competitorDetail.metrics.churnRate
Low; multi-year contracts drive retention
| competitors.competitorDetail.metrics.fundingStage | competitors.competitorDetail.metrics.fundingAmount | competitors.competitorDetail.metrics.fundingDate |
|---|---|---|
| Seed | $1M | 2009-02-01 |
| Series A | $12M | 2014-03-12 |
| Series B | $45M | 2016-09-01 |
| IPO (SPAC) | $1.6B | 2021-09-17 |
- Mission-driven experimentation
- Collaborative, cross-disciplinary teams
- Strong focus on sustainability
- Commitment to diversity and inclusion
- Inc. 5000 Fastest Growing Companies (2022) - Inc. Magazine
- MIT Technology Review 50 Smartest Companies (2019)
| competitors.competitorDetail.news.title | competitors.competitorDetail.news.publishedOn | competitors.competitorDetail.news.readMore |
|---|---|---|
| Ginkgo Bioworks launches partnership with Novo Nordisk to advance cell therapy manufacturing | 2024-04-10 | Fierce Biotech |
| Ginkgo Bioworks Reports Q1 2024 Results; Raises Full-Year Guidance | 2024-05-08 | Seeking Alpha |